Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001410578-23-001577
Filing Date
2023-08-07
Accepted
2023-08-07 16:06:31
Documents
50
Period of Report
2023-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q enzn-20230630x10q.htm   iXBRL 10-Q 707704
2 EX-31.1 enzn-20230630xex31d1.htm EX-31.1 15467
3 EX-32.1 enzn-20230630xex32d1.htm EX-32.1 7234
  Complete submission text file 0001410578-23-001577.txt   3080826

Data Files

Seq Description Document Type Size
4 EX-101.SCH enzn-20230630.xsd EX-101.SCH 31025
5 EX-101.CAL enzn-20230630_cal.xml EX-101.CAL 19498
6 EX-101.DEF enzn-20230630_def.xml EX-101.DEF 103691
7 EX-101.LAB enzn-20230630_lab.xml EX-101.LAB 226234
8 EX-101.PRE enzn-20230630_pre.xml EX-101.PRE 177091
44 EXTRACTED XBRL INSTANCE DOCUMENT enzn-20230630x10q_htm.xml XML 309901
Mailing Address 20 COMMERCE DRIVE, SUITE 135 CRANFORD NJ 07016
Business Address 20 COMMERCE DRIVE, SUITE 135 CRANFORD NJ 07016 732-980-4500
ENZON PHARMACEUTICALS, INC. (Filer) CIK: 0000727510 (see all company filings)

EIN.: 222372868 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 000-12957 | Film No.: 231147622
SIC: 2836 Biological Products, (No Diagnostic Substances)